Medical Writing Authors and Authorship The sun never sets on transparency
emwa-spring-2016png

Volume 25, Issue 1 - Authors and Authorship

The sun never sets on transparency

Abstract

The financial relationships between the pharmaceutical and device industries and healthcare practitioners appear frequently in the spotlight because of their potential to create bias and influence prescribing choices. Public disclosure of these transactions may help patients make informed choices about their healthcare practitioners and may help reduce healthcare costs. The US Sunshine Act, a Federal law that requires disclosure of transactions between industry and healthcare practitioners, was passed in 2010. Similar disclosure laws and codes now exist globally. Unfortunately, none of the current requirements are clear about the reportability of industry support for medical writing and editorial services. Regardless, medical writers should be aware of these requirements, which can help them as they forge relationships with authors.

Download the full article

References

  1. Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3Good Publication Practice for Company- Sponsored Research (GPP3). Annals of Internal Medicine. 2015;163(6): 461-464.
  2. ICMJE. Recommend at ions for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2013; Available from: http://www.ICMJE.org
  3. United States 111 Congress HR 3590. Patient protection and affordable care act. 2010:111-148.
  4. Centers for Medicare and Medicaid Services. Federal register. Department of Health and Human Services; 2013:9457-9528.
  5. Jarvies D, Coombes R, Stahl-Timmins W. Open Payments goes live with pharma to doctor fee data: first analysis. BMJ (Clinical research ed.). 2014-10- 01 16:46:40 2014;349.
  6. Morain SR, Flexner C, Kass NE, Sugarman J. Forecast for the Physician Payment Sunshine Act: Partly to Mostly Cloudy?Forecast for the Physician Payment Sunshine Act. Annals of Internal Medicine. 2014;161(12): 915-916.
  7. Centers for Medicare and Medicaid Services. CMS implements final rule change for open payments. In: Services CfMaM, ed. Vol Pubilc law no. 111- 152: Centers for Medicare and Medicaid Services; 2014.
  8. Andrews RE, Schwartz AY, Meehan P, et al. Final Sunshine Act letter to Marilyn Tavenner. 2014.
  9. Upton F. HR6-21st century cures act. 2015.
  10. Grassley C. S.213-Provider Payment Sunshine Act. 2015.
  11. Campbell DJ, Sharkey BP. Ready or not, full speed ahead for the global transparency movement. 2015; Available from: http://porziolifesciences.com/resources/publications
  12. European Federation of Pharma ceut - ical Industries and Associations. EFPIA HCP/HCO disclosure code. 2014:1- 15.
  13. European Federation of Pharmaceutical Industries and Associations. EFPIA code on disclosure of transfers of value from pharma - ceutical companies to healthcare professionals and healthcare organisations: Frequently asked questions. 2014; Available from: http://transparency.efpia.eu/countries/download/11/document_2/faq–disclosure-code.pdf
  14. The International Society for Medical Publication Professionals. ISMPP Sunshine Act information update. 2014; Available from: http://www.ismpp.org/assets/docs/Inititives/Sunshine_Act/sunshine%20act%20interpretation%20update_february%202014_final.pdf
  15. Toroser D, DeTora L, Cairns A, et al. The Sunshine Act and medical publications: Guidance from professional medical associations. Postgrad Med. 2015/11/04 2015;127(7):752-757.
  16. Wechsler R, Hauser RA, French J, the Clinician Investigator C. Who is helping whom? Manuscript support and transfer of value. Annals of Neurology. 2015;77(2):353-355.
  17. Ratain MJ. Forecasting unanticipated consequences of “the Sunshine Act”: mostly cloudy. JCO. 2014;32(22): 2293-2295.

Search

Articles

Authors and Authorship
Letter from the Editor
President’s Message
Ghostwriting prevalence among AMWA and EMWA members (2005 to 2014)
The sun never sets on transparency
GPP3 – what is it, why is it necessary and what is new?
Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature
Perspective from a leading scientific author: An interview with Professor Ruth Roberts on authors and authoring
Authorship of clinical trial documents
Project management in medical publication writing: A less explored avenue in pharmaceutical companies and clinical research organisations
Never say never! Returning to full-time employment after freelancing
Fifth EMWA freelance business survey
Journal Watch
In the Bookstores
The Webscout
Regulatory Writing: Authorship issues in regulatory documents
English Grammar and Style
Medical Communication
Lingua Franca and Beyond
Gained in Translation
Medical Writing Teaching
Profile: An interview with Phil Leventhal
EMWA’s 2016 Webinar Programme
Out on our own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

  • Victoria White (Tampa, Florida, USA) Email: MEW@emwa.org
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: